February 2025, Vol 15, No 2
The common issue addressed by lawsuits is the removal of human beings to review and make determinations regarding the appropriateness of care. While mainly focused now on algorithms, these factors seem to be an indicator of future health plan litigation involving artificial intelligence. Read More ›
A lab created a drug-matching platform that uses artificial intelligence (AI) to help researchers, clinicians and, most importantly, patients find additional uses for drugs that have already gone through clinical trials and received approval from the FDA. Read More ›
Patients diagnosed with high-risk multiple myeloma persistently exhibit markedly inferior survival rates compared with patients without high-risk disease, despite the advancements in novel therapeutic agents available today. Read More ›
The intravenous administration of the anti-CD38 antibody isatuximab, in conjunction with pomalidomide and dexamethasone, has received approval for the treatment of patients with relapsed or refractory multiple myeloma (RRMM), as established by the findings of the ICARIA-MM study (NCT02990338) and presented at the International Myeloma Society 21st Annual Meeting & Exposition. Read More ›
Bortezomib in combination with lenalidomide and dexamethasone (VRd) represents a standard initial treatment option for both transplant-eligible and -ineligible patients with multiple myeloma, according to study findings that were presented at the 21st International Myeloma Society Annual Meeting. Read More ›
In patients with newly diagnosed multiple myeloma (NDMM), the use of anti-CD38 monoclonal antibodies (mAbs) enhances the effectiveness of standard treatment protocols, according to a study presented at the 66thAmerican Society of Hematology Annual Meeting & Exposition in San Diego, CA. Read More ›
Patient experience has become a cornerstone of medical office operations. It significantly influences patient outcomes, satisfaction, and overall well-being. If you are interested in a deeper dive into this topic, find more information for a comprehensive 3-hour webinar on Tuesday, March 11 from 11 a.m. – 2 p.m. CST . Read More ›